Table 1.
List of monoclonal antibodies approved by the FDA for cancer treatment
| Name of monoclonal antibody | Type of cancer treatment |
|---|---|
| Epidermal Growth Factor Receptor (EGFR) | |
| Amivantamab | non-small cell lung cancer (NSCLC) |
| Cetuximab | metastatic colorectal cancer and head and neck cancer |
| Nimotuzumab | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma |
| Panitumumab | colorectal cancer |
|
| |
| VEGF | |
|
| |
| Bevacizumab | colorectal cancer, glioblastoma, and breast cancer |
| Ramucirumab | gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma |
|
| |
| Programmed Cell Death Protein -1 (PD-1) | |
|
| |
| Nivolumab | unresectable or metastatic melanoma |
| Pembrolizumab | unresectable or metastatic solid tumor with certain genetic anomalies melanoma and other cancers |
| Cemiplimab | metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC |
|
| |
| Programmed death-ligand 1 (PD-L-1) | |
|
| |
| Atezolizumab | urothelial carcinoma, NSCLC, triple-negative breast cancer, small cell lung cancer, and hepatocellular carcinoma |
| Avelumab | Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma |
| Durvalumab | certain types of bladder and lung cancer |
|
| |
| Human Epidermal Growth Factor Receptor 2 (HER2) | |
|
| |
| Ertumaxomab | breast cancer, etc. |
| Margetuximab | breast cancer |
| Pertuzumab | cancer |
| Trastuzumab | breast cancer |
| Trastuzumab duocarmazine | breast cancer |
| Trastuzumab emtansine | breast cancer |
|
| |
| CD20 | |
|
| |
| Rituximab | chronic lymphocytic leukemia |
| Human or humanized anti-CD20 antibodies | B-cell non-Hodgkin’s lymphoma |
| Ibritumomab | treatment of non-Hodgkin’s lymphoma |
|
| |
| CD-30 | |
|
| |
| Brentuximab (+mono methyl auristatin E) | Hodgkin’s lymphoma |
|
| |
| CD52 | |
|
| |
| Alemtuzumab | chronic lymphocytic leukemia |
|
| |
| CTLA-4 | |
|
| |
| Ipilimumab (Yervoy) | Melanoma |